Asset
NAMODENOSON
CAN-FITE BIOPHARMA LTD AMERICAN DEPOSITARY SHARES EACH REPRESENTING TWO (2) ORDINARY SHARES
Revenue
No revenue reported in loaded filings.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00790218 | phase1_2 | completed | 2009-02-01 | 2012-12-01 | Can-Fite BioPharma | A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma |
| NCT00790673 | phase1_2 | completed | 2009-07-01 | 2011-06-01 | Can-Fite BioPharma | A Phase 1/2 Study of CF102 in Patients With Chronic Hepatitis C Genotype 1 |
| NCT02927314 | phase2 | completed | 2017-11-27 | 2020-03-01 | Can-Fite BioPharma | A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease |
| NCT06387342 | phase2 | recruiting | 2024-11-10 | 2026-07-15 | Can-Fite BioPharma | Namodenoson Treatment of Advanced Pancreatic Cancer |
| NCT05201404 | phase3 | recruiting | 2023-03-15 | 2026-02-01 | Can-Fite BioPharma | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis |
FDA applications (0)
This company has no applications containing this asset.